07:10 EDT Neurocrine sees 2023 Ingrezza net sales $1.82B-$1.84B
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
- Neurocrine Biosciences (NBIX) Q3 Earnings Cheat Sheet
- Neurocrine assumed with an Overweight at Cantor Fitzgerald
- Neurocrine price target raised to $143 from $137 at BofA
- Neurocrine price target raised to $135 from $125 at Leerink